Jorge Cortes, MD

Alexander Bick, physician-scientist studying clonal hematopoiesis in sickle cell disease. Jorge Cortes, cancer center director researching chronic myeloid leukemia therapies. They discuss asciminib's novel mechanism, superior efficacy and safety in newly diagnosed CML, and treatment-free remission goals. They also explore an unexpected higher prevalence of micro-clonal hematopoiesis in children with sickle cell disease and its distinct dynamics.

Dr. Jorge Cortes, a leading hematologist-oncologist from the Georgia Cancer Center, shares his expertise on Chronic Myeloid Leukemia (CML) management. He emphasizes the critical role of initial workups and patient-centered decision-making in treatment planning. Cortes discusses the latest tyrosine kinase inhibitors like Asiminib and Ponatinib, tailoring therapies to patient goals, and the importance of monitoring response. He also explores managing treatment-related toxicities and when to consider transplantation for advanced CML, revealing vital insights for both professionals and patients.

Experts Jorge Cortes and Mhairi Copland discuss recent updates in chronic myeloid leukemia (CML), including treatment strategies for refractory disease, novel agents, and clinical trial updates from the OPTIC and ASCEMBL trials. They highlight the use of new drugs and optimized doses, personalized approaches, and the potential of combining TKI therapy with immunological approaches for improved responses in CML patients.